Business Model Breakdown
How Elevance Health Inc Makes Money
ELV
Market Cap
$80.9B
Profit Margin
2.6%
The Short Version
Elevance Health primarily generates revenue by providing health insurance benefits to millions of members across various types of plans, including employer-sponsored, Medicaid, Medicare Advantage, and individual Affordable Care Act (ACA) plans, mainly in over a dozen U.S. states. They collect premiums from members and employers, then manage the associated healthcare costs. A growing portion of their business comes from their Carelon services segment, which provides integrated health solutions like pharmacy benefits management, behavioral health, clinical care, and digital tools, not only to their own insurance members but also to external clients, aiming to improve health outcomes and reduce overall healthcare spending.
Where the Revenue Comes From
Health Benefits (Insurance premiums and administrative fees) (~86% of revenue)
Carelon Services (Pharmacy benefits, behavioral health, clinical care, digital solutions) (~14% of revenue)
Who buys: Individuals, employer groups (large and small businesses), state governments (Medicaid programs), and the federal government (Medicare Advantage programs).
Why It Works (Competitive Advantages)
- ✔Vast provider networks and established brand recognition across multiple states.
- ✔Significant scale providing cost advantages and bargaining power.
- ✔Integrated Carelon services offering a diversified revenue stream beyond traditional insurance.
Economic Moat: Wide (Efficient Scale, Switching Costs, Intangible Assets/IP, Network Effects)
What Our Analysis Says
DVR Score as of May 1, 2026
Elevance Health remains a dominant, financially robust player in the mature healthcare insurance market. Its Q1 2026 performance showed a beat on adjusted EPS and raised FY26 guidance, supported by strong operating cash flow and continued growth in the Carelon services segment (+7.9% YoY). However, these positives are tempered by a significant $935 million accrual for potential CMS Medicare Advantage data reporting exposure, a decline in GAAP EPS YoY, and a rising benefit ratio. While the company's strategic focus on integrated 'whole health' and Carelon is sound for maintaining leadership and driving stable growth, these initiatives, along with its current large market capitalization of $81.74B, do not position it for a 10x return within 3-5 years. It is a solid, defensive investment rather than a high-risk, high-reward exponential growth opportunity. The new Q1 earnings and related disclosures do not materially alter its 10x growth potential from the previous assessment, hence the consistent low score.